Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

gw pharmaceuticals

  • Home
  •  
  • gw pharmaceuticals



  • Most Read
  • Latest Comments
  • Aussie opioid manufacturer cashed up following $33m sale of facility
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Aussie opioid manufacturer cashed up following $33m sale of facility
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Aussie opioid manufacturer cashed up following $33m sale of facility
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Aussie opioid manufacturer cashed up following $33m sale of facility
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Aussie opioid manufacturer cashed up following $33m sale of facility
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • MVP eyes increased global distribution of Penthrox green whistle after raising $20m
    MVP eyes increased global distribution of Penthrox green whistle after raising $20m
    • News

  • Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    Regeneus begins to etch pathway to drug commercialisation, exuding confidence in their tech
    • News

  • Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    • News

  • Wellfully set to jump into $9 billion market with FDA registration for their knee pain patch
    Wellfully set to jump into $9 billion market with FDA registration for their knee pain patch
    • News

  • Aussie opioid manufacturer cashed up following $33m sale of facility
    Aussie opioid manufacturer cashed up following $33m sale of facility
    • News

  • Aussie opioid manufacturer cashed up following $33m sale of facility
    • News

    Aussie opioid manufacturer cashed up following $33m sale of facility

    While prescription opioids have been getting a pretty bad rap over the past few years amid revelations in the US about a certain Sackler family, they still have a vital role to play in healthcare where good guys like Palla Pharma (ASX: PAL) have strengthened their balance sheet with the sale of their manufacturing facility

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.